Annovis Bio Inc (ANVS NYSE) stock market data APIs
$1.1919
0.02(1.7%)
as of September 10, 2026
Try our APIs with
free plan!
Annovis Bio Inc Financial Data Overview
Price chart is built with
Anychart
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Prev. Close
1.1919
Open
1.2162
High
1.2494
Low
1.1679
52 wk Range
1.17-5.5
Market Cap
50 701 K
Shares Outstanding
42 606 K
EPS
-0.4
Beta
1.236
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Annovis Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Annovis Bio Inc data using free add-ons & libraries
Get Annovis Bio Inc Fundamental Data
Annovis Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -0.44
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Annovis Bio Inc News
New
Real Parkinson’s Disease Hope from Jupiter Neurosciences
By Mike Sheikh Parkinson's Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. Th...
The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
The Alzheimer's disease market dynamics are anticipated to change due to the expected launch of emerging therapies, such as Masupirdinea (Suven Life Sciences), Trontinemabb (Roche), Buntanetap (Annovi...
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational ora...
Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period
(RTTNews) - Annovis Bio, Inc. (ANVS), a clinical-stage biotechnology company, on Tuesday announced that it regained compliance with the New York Stock Exchange (NYSE) continued listing standards. Nota...
Get Annovis Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
